Brentuximab Vedotin

点击蓝字关注我们编者按2025年欧洲血液学会（EHA）年会与国际恶性淋巴瘤会议（ICML）相继在米兰与卢加诺召开，聚焦全球血液肿瘤学的最新进展。上海交通大学医学院附属瑞金医院赵维莅教授团队携多项研究成果重磅亮相国际舞台，全面覆盖弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤及外周T细胞淋巴瘤等多个亚型，充分展现中国团队在机制探索、精准分型、免疫治疗及真实世界研究等方面的持续深耕与系统布局。其中，关于泽布替尼联合来那度胺和利妥昔单抗（ZR2）治疗高龄体弱DLBCL患者的PEARL研究更是入选ICML大会LBA摘要（Latest Breakthrough Abstract）报告，显示其与标准减量化疗（R-miniCHOP）疗效相当，有望成为化疗替代方案，标志着中国原创治疗策略的重大突破。GUIDANCE-02研究探索基于遗传亚型指导的一线个体化治疗模式，也正在国内多中心稳步推进，反映出从科研设计到临床转化的高质量闭环。本期特整理这些研究的核心亮点，带您一览淋巴瘤领域的前沿进展。弥漫大B细胞淋巴瘤01摘要号：ICML#LBA2标题：Zanubrutinib plus lenalidomide and rituximab versus R-miniCHOP in unfit or frail patients with newly diagnosed diffuse large B-cell lymphoma aged 70 years or older中文标题：泽布替尼联合来那度胺和利妥昔单抗与R-miniCHOP用于治疗70岁及以上新诊断不适合强化治疗或虚弱弥漫大B细胞淋巴瘤患者的对比研究类型：LBA第一作者：许彭鹏研究结论：本研究（PEARL）结果显示，ZR2方案（泽布替尼联合来那度胺和利妥昔单抗）在完全缓解率上与R-miniCHOP相当，且两组基线特征平衡，提示ZR2方案有望成为70岁及以上新诊断不适合强化治疗或虚弱弥漫大B细胞淋巴瘤（DLBCL）患者一种有效且潜在更安全的无化疗治疗选择。02摘要号：ICML#OT05（在研临床试验）标题：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma中文标题：GUIDANCE-02研究：一项基于遗传亚型指导免疫化疗治疗弥漫大B细胞淋巴瘤的多中心、随机、III期临床研究类型：口头报告第一作者：赵维莅研究进展：GUIDANCE-02是一项正在进行的、多中心、随机、III期临床研究，旨在评估基于遗传亚型指导的免疫化疗方案（R-CHOP-X）相较于标准R-CHOP在新诊断的中高危弥漫大B细胞淋巴瘤（DLBCL）患者中的疗效和安全性。研究采用38基因分类算法“LymphPlex” 对患者进行分型，并根据不同亚型个性化添加靶向药物（如奥布替尼、来那度胺或地西他滨）。主要终点为无进展生存期（PFS），目前已在中国58家中心已经完成1100例入组，结果有望进一步推动DLBCL的精准治疗策略。03摘要号：EHA#PS1956标题：INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (PR-ICE) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I/II STUDY (PRIDE STUDY)中文标题：泊马度胺联合利妥昔单抗、异环磷酰胺、卡铂和依托泊苷（PR-ICE）治疗复发/难治性弥漫性大B细胞淋巴瘤的Ⅰ/Ⅱ期研究的中期分析（PRIDE研究）类型：壁报第一作者：许彭鹏研究结论：复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）治疗选择有限，预后较差。本研究显示，PR-ICE方案在R/R DLBCL患者中展现出较高的疗效与可接受的安全性。泊马度胺与R-ICE联合的确定最大耐受剂量（MTD）在临床上诱导了显著的完全缓解率。这些结果支持将PR-ICE作为R/R DLBCL挽救治疗方案进行进一步研究。04摘要号：EHA#PF916标题：POSITRON EMISSION TOMOGRAPHY-ADAPTED THERAPY IN LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: 4-YEAR RESULTS OF A RANDOMIZED, PHASE III, NON-INFERIORITY TRIAL中文标题：低危弥漫大B细胞淋巴瘤PET-CT调整的治疗：一项随机、III期、非劣效性试验的4年随访结果类型：壁报第一作者：施晴研究结论：本研究显示，对于中期PET-CT阴性的低危、非巨块型弥漫大B细胞淋巴瘤（DLBCL）患者，4个周期的R-CHOP方案加4个周期的利妥昔单抗方案可提供与6个周期的R-CHOP方案加2个周期的利妥昔单抗方案相当的长期临床疗效。该PET-CT调整性治疗策略在保证持续缓解的同时，有望减少化疗强度，为低危DLBCL的治疗管理提供了新思路。05摘要号：ICML#294标题：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China中文标题：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与治疗结局：中国大规模真实世界研究类型：壁报第一作者：许彭鹏研究结论：本项中国大规模真实世界研究显示，弥漫大B细胞淋巴瘤（DLBCL）具有高度遗传异质性，不同分子亚型在治疗模式和临床结局上呈现出显著差异。尽管R-CHOP仍为主要一线方案，但部分患者接受了靶向治疗、CAR-T或自体移植等强化治疗。研究结果为推进基因分型指导下的精准治疗提供了重要依据，有望优化DLBCL的治疗策略与预后管理。06摘要号：EHA#PS2162标题：HIGH EFFICACY AND SAFETY OF A NOVEL ANTI-CD20 CAR-T CELL THERAPY, LY007 IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA中文标题：新型抗CD20 CAR-T细胞疗法LY007在复发或难治性B细胞非霍奇金淋巴瘤中的高效性和良好安全性类型：壁报第一作者：盛凌霜研究结论：LY007在最高剂量水平（DL3）下显示出良好的安全性、可观的疗效及稳健的药代动力学特征，未观察到剂量限制性毒性（DLT）、神经毒性或≥3级细胞因子释放综合征 (CRS)。LY007的生物利用度 (BOR) 达到91.7%，包括高肿瘤负荷、既往接受过CD19 CAR-T治疗和自体干细胞移植 (ASCT) 的患者。07摘要号：EHA#PF971标题：SAFETY AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN CHINESE CD30-POSITIVE LYMPHOMA ADULTS: AN INTERIM ANALYSIS FROM BRAVE STUDY中文标题：维布妥昔单抗在中国CD30阳性淋巴瘤成人患者中的安全性和有效性：BRAVE研究的中期分析类型：壁报第一作者：蔡铭慈研究结论：本研究结果进一步支持维布妥昔单抗(BV)联合化疗在CD30阳性淋巴瘤治疗中疗效确切、耐受性良好，是一种有价值的治疗选择。BRAVE研究仍在持续进行中，后续将公布长期随访结果。套细胞淋巴瘤01摘要号：EHA#PS1969标题：ORELABRUTINIB PLUS BENDAMUSTINE-RITUXIMAB (OBR) VERSUS BENDAMUSTINE-RITUXIMAB (BR) IN TRANSPLANT-INELIGIBLE, INTERMEDIATE- TO HIGH-RISK MANTLE CELL LYMPHOMA (MCL)中文标题：奥布替尼联合苯达莫司汀-利妥昔单抗（OBR）与苯达莫司汀-利妥昔单抗（BR）治疗不适合移植的中高危套细胞淋巴瘤（MCL）患者的对比研究类型：壁报第一作者：王黎研究结论：免疫化疗仍是套细胞淋巴瘤（MCL）的标准治疗方案，但携带高危特征，如TP53突变、母细胞样或多形性组织学亚型，或高MCL国际预后指数[MIPI]评分（伴Ki-67增殖指数[Ki-67%]>30%）的患者预后较差。本研究初步数据表明，OBR方案较BR方案可减少高危MCL患者的疾病进展事件。后续将公布疗效、安全性及生物标志物的更多研究结果。滤泡性淋巴瘤01摘要号：EHA#PS1906标题：NATIONWIDE SURVEY OF THE JOURNEY OF PATIENTS LIVING WITH FOLLICULAR LYMPHOMA IN CHINA: REAL-WORLD INSIGHTS AND ANALYSIS中文标题：中国滤泡性淋巴瘤患者诊疗旅程的全国性调研：真实世界见解与分析类型：壁报第一作者：赫洋研究结论：本研究首次在全国范围内系统调研了中国滤泡性淋巴瘤（FL）患者的真实诊疗旅程，发现患者在不同治疗阶段的目标和需求存在明显差异，初治阶段以治愈和延长生存为主，复发后则更关注避免复发和治疗选择；影响治疗决策的主要因素包括疗效、安全性及经济负担；信息获取渠道也随病程进展由网络转向专业医疗人员。该研究为优化患者管理、制定个体化支持策略提供了重要的真实世界依据。02摘要号：EHA#PF897、ICML#178标题：CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT中文标题：结外受累滤泡性淋巴瘤患者的临床特征与分子异质性分析类型：壁报第一作者：李悦驰研究结论：本研究发现，多发结外侵犯（ENI）是滤泡性淋巴瘤患者接受利妥昔单抗联合化疗时的重要不良预后因素，相关基因突变（如KMT2D、CREBBP、CARD11、STAT6）及免疫通路下调可能在其中发挥作用；但在接受利妥昔单抗联合来那度胺（R2）免疫治疗的患者中，ENI对预后的负面影响不再显著，提示免疫治疗有望克服ENI带来的不良影响，并为机制导向的个体化治疗提供了新的思路。外周T细胞淋巴瘤01摘要号：ICML#62标题：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with  Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)中文标题：帕博利珠单抗联合放疗治疗新诊断早期虚弱自然杀伤/T细胞淋巴瘤患者的Ⅱ期临床试验（IELSG50）类型：口头报告第一作者：钟慧娟研究结论：NK/T细胞淋巴瘤（NKTCL）是一种侵袭性极高的淋巴瘤，常与EB病毒感染和免疫检查点高表达相关。对于不适合化疗的患者，治疗选择有限。免疫检查点抑制剂已在复发/难治性NKTCL中展现出疗效。本研究显示，帕博利珠单抗联合放疗在新诊断、早期、虚弱NKTCL患者中展现出良好的疗效和安全性，尤其适用于中高危患者。免疫检查点抑制剂有望作为早期NKTCL一线治疗的替代策略。02摘要号：ICML#163标题：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study中文标题：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果类型：口头报告第一作者：程澍研究结论：外周T细胞淋巴瘤（PTCL）是一类侵袭性强、异质性高的T细胞肿瘤，目前缺乏有效治疗手段。不同基因特征的患者对治疗的反应存在差异。本研究显示，他泽司他联合Amdizalisib在复发/难治性PTCL中表现出良好疗效，尤其在血管免疫母细胞T细胞淋巴瘤（AITL）亚型中缓解率较高。TET2和RHOA共突变的患者可能预示更佳治疗反应。后续需更大样本进一步验证这些发现。专家简介赵维莅 教授上海交通大学医学院附属瑞金医院主任医师，教授，博士生导师国家杰出青年科学基金获得者教育部长江学者特聘教授科技部万人计划领军人才百千万人才工程国家级人选上海交通大学医学院附属瑞金医院副院长上海市重中之重临床医学中心主任上海血液学研究所所长中华医学会血液学分会副主任委员，淋巴细胞疾病学组组长中国病理生理学会理事，实验血液学专委会副主任委员中国临床肿瘤协会抗淋巴瘤联盟副主席致力于淋巴细胞恶性疾病的临床和基础研究，以通讯/第一作者在《The New England Journal of Medicine 》《CANCER CELL》、《NATURE GENETICS》、《BLOOD》《LANCET HAEMATOL》、《SIGNAL TRANSDUCT TARGET THER》、《J HEMATOL ONCOL》等国际权威杂志发表文章110余篇，总影响因子超过1500。相关成果以第一完成人获国家科学技术进步奖二等奖1项，省部级一等奖6项，获国家发明专利15项，主持国家科技部重点研发计划、863 重大项目、国家自然科学基金重点项目多项。先后荣获 “全国卫生系统先进工作者”、“全国三八红旗手”、中国青年女科学家奖、EBMT青年领袖奖、吴阶平医药创新奖、谈家桢生命科学奖、上海市科技精英等多项荣誉（来源：《肿瘤瞭望–血液时讯》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

Antibody-drug conjugates (ADCs) are revolutionizing cancer care by combining precision targeting with potent cytotoxins, offering hope for hard-to-treat tumors. ADCs are transforming cancer therapy-uniting accuracy with lethal efficacy, they offer a beacon of hope for patients with limited treatment options and challenging malignancies.” — DataM Intelligence AUSTIN, TX, UNITED STATES, June 17, 2025 / EINPresswire.com / -- Antibody-Drug Conjugates (ADCs): A New Era in Precision Cancer Treatment The oncology world is undergoing a revolutionary transformation—and at the heart of this transformation are Antibody-Drug Conjugates (ADCs). These sophisticated drugs marry the pinpoint targeting abilities of monoclonal antibodies with the cell-killing power of chemotherapy agents. The result? A new standard of care that delivers cytotoxic therapy directly to cancer cells with reduced harm to healthy tissues. Download CI Sample Report: https://www.datamintelligence.com/strategic-insights/ci/antibody-drug-conjugates-adcs The ADC Blueprint: Three Critical Components An ADC is built from three essential elements that work in synergy to seek and destroy cancer cells: - Monoclonal Antibody (mAb): This biologic component identifies and binds to specific antigens on the surface of cancer cells. For instance, trastuzumab targets the HER2 receptor, which is overexpressed in some breast and gastric cancers. - Linker: This chemical bridge attaches the antibody to the drug. The linker must be stable in the bloodstream but easily cleaved once inside the cancer cell. Linkers come in cleavable types (triggered by pH or enzymes) and non-cleavable forms that release the drug only after cellular degradation. - Cytotoxic Payload: These are highly potent chemotherapy drugs—such as MMAE (a microtubule inhibitor) or SN-38 (a topoisomerase inhibitor)—capable of killing cells even at low concentrations. How ADCs Work: A Targeted Strike on Tumors The mechanism of ADCs is elegantly efficient: - Target Binding: The monoclonal antibody binds specifically to a cancer-specific antigen. - Internalization: The cancer cell engulfs the ADC via receptor-mediated endocytosis. - Payload Release: Inside the cell, the linker is cleaved, releasing the cytotoxic drug. - Cell Death: The released drug disrupts critical cellular functions, triggering apoptosis (programmed cell death). This targeted strategy minimizes collateral damage to healthy tissues and reduces the side effects typically associated with traditional chemotherapy. Latest Innovations & Trends in ADC Development The field of ADCs is evolving at a breathtaking pace. Several cutting-edge trends are emerging in both preclinical and clinical research: - Smarter Linkers and Payloads: New linker designs improve stability in circulation and allow more selective release of drugs in tumor environments. Payloads are becoming more diverse, potent, and even immunomodulatory. - Multi-Antigen Targeting: Bispecific ADCs are in development to address tumors with heterogeneous antigen expression, thereby increasing efficacy. - Combination Therapies: ADCs are being trialed alongside immune checkpoint inhibitors or other modalities to amplify response rates in resistant tumors. - Enhanced Manufacturing: Better conjugation techniques, including site-specific approaches, are improving the safety, consistency, and scalability of ADC production. Approved ADCs: A Growing Class of Blockbusters As of early 2025, several ADCs have received FDA approval and are generating robust clinical and commercial outcomes: - Enhertu ® (Daiichi Sankyo/AstraZeneca): A HER2-targeting ADC approved for breast, gastric, and lung cancers. It recorded approximately $3.75 billion in sales in 2024 and is considered best-in-class for HER2-positive tumors. - Trodelvy ® (Gilead Sciences): The first Trop-2-targeting ADC for triple-negative breast cancer (TNBC) and bladder cancer. Despite its moderate toxicity, Trodelvy is a market leader with ~$1.32 billion in 2024 sales. - Adcetris ® (Seagen, now part of Pfizer): Approved since 2011, this CD30-targeting ADC is a game-changer for Hodgkin lymphoma and other hematologic malignancies. Its consistent performance places it as a top ADC brand. - Padcev ® (Seagen/Pfizer): Targeting Nectin-4, this ADC is FDA-approved for urothelial carcinoma and is known for its first-in-class status and strong market uptake. Next-Gen ADCs in the Pipeline The ADC pipeline is rich and varied, with numerous candidates expected to reach approval in the next few years: - Rinatabart Sesutecan is an advanced HER2-targeting ADC designed to offer better safety and efficacy than current standards. - Teliso-V from AbbVie is showing promise in non-small cell lung cancer (NSCLC), addressing unmet needs in difficult tumor types. - Elahere ® is approved for platinum-resistant ovarian cancer and is being developed for other solid tumors. With over 100 ADC candidates in various stages of development, the coming decade will likely witness a surge of new approvals and expanded indications. Market Size and Future Outlook In 2024, the global ADC market was valued at $13.81 billion. The market is projected to grow at a CAGR of 15–17% through 2033. This expansion is driven by: - Rising incidence of difficult-to-treat cancers. - Clinical success of FDA-approved ADCs. - Increased R&D investments from pharmaceutical and biotech companies. - Expanding indications and geographic approvals. North America leads the market, but Asia-Pacific—particularly China and South Korea—is rapidly catching up with an aggressive push in ADC research, trials, and local manufacturing. Challenges and Unmet Needs Despite their advantages, ADCs still face several hurdles: - Tumor Heterogeneity: Not all tumors express target antigens uniformly. This limits efficacy. Emerging bispecific ADCs and predictive biomarkers are potential solutions. - Drug Resistance: Tumors can evade ADC therapy by reducing antigen expression or pumping out the payload. Developers are exploring alternative payloads and combination regimens. - Off-Target Toxicity: ADCs can sometimes harm healthy cells. This is being addressed through better linkers, optimized antibody affinities, and refined dosing schedules. - Solid Tumor Penetration: Dense tumor microenvironments block ADC access. Researchers are developing smaller, nanobody-based ADCs for deeper tissue penetration. - High Costs and Complex Manufacturing: ADCs are expensive to produce and difficult to scale. Advances in conjugation technologies and the emergence of biosimilar ADCs could ease the burden. Competitive Landscape and Key Players The ADC sector is both competitive and collaborative, marked by M&A activity, strategic alliances, and innovation-led expansion: - Pfizer’s $43 billion acquisition of Seagen in 2024 solidified its leadership in the ADC space, adding Adcetris ® , Padcev ® , and Tivdak ® to its oncology portfolio. - Gilead’s $21 billion Immunomedics acquisition brought Trodelvy ® into its hands, with the company now expanding into new indications. - AstraZeneca and Daiichi Sankyo’s partnership continues to yield market-leading HER2-targeted ADCs like Enhertu ® . - AbbVie’s $10 billion investment in ImmunoGen reflects its strategic bet on next-generation ADCs for solid tumors such as NSCLC. Book Free CI Consultation Call: https://www.datamintelligence.com/strategic-insights/ci/antibody-drug-conjugates-adcs The Road Ahead: Beyond Cancer While oncology remains the primary focus, ADCs are also being explored for autoimmune and infectious diseases. Researchers are investigating ADCs that can: - Deliver immunosuppressive payloads for autoimmune diseases like lupus. - Target bacterial pathogens with precision antibiotics attached to monoclonal antibodies. Though early-stage, these developments could dramatically widen the scope of ADC applications. Conclusion: ADCs at the Frontier of Precision Medicine Antibody-drug conjugates stand as one of the most exciting innovations in modern oncology. They embody the future of precision medicine—where therapy is tailored, effective, and kinder to the patient. As the science evolves, ADCs are expected to transition from niche treatments to mainstream therapies across a broad range of cancers and beyond. Read Related CI Reports: 1. Systemic Sclerosis | Competitive Intelligence 2. Sjogren Disease | Competitive Intelligence Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 sai.k@datamintelligence.com Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.